R Bugat
Overview
Explore the profile of R Bugat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
1695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scotte F, Herve C, Oudard S, Bugat M, Bugat R, Farsi F, et al.
Eur J Cancer
. 2012 Dec;
49(5):1090-6.
PMID: 23231983
Background: Supportive care in cancer (SCC) was further enhanced in the Second National Cancer Act decreed in December 2009. The aim of our study was to assess current SCC efficacy....
2.
Ychou M, Raoul J, Douillard J, Gourgou-Bourgade S, Bugat R, Mineur L, et al.
Ann Oncol
. 2009 Jan;
20(4):674-80.
PMID: 19179549
Background: This multicenter adjuvant phase III trial evaluated the addition of irinotecan to LV5FU2 in colon cancer patients at high risk of relapse. Patients And Methods: A total of 400...
3.
Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al.
Ann Oncol
. 2008 Jun;
19(8):1450-1457.
PMID: 18558665
Background: We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients...
4.
Balin-Gauthier D, Delord J, Pillaire M, Rochaix P, Hoffman J, Bugat R, et al.
Br J Cancer
. 2008 Jan;
98(1):120-8.
PMID: 18182978
Preclinical studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum derivative, is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors....
5.
Van Cutsem E, Verslype C, Beale P, Clarke S, Bugat R, Rakhit A, et al.
Ann Oncol
. 2007 Nov;
19(2):332-9.
PMID: 17986625
Background: Dysregulation of the epidermal growth factor receptor (HER1/EGFR) has been reported in colorectal cancer (CRC). Erlotinib is a potent inhibitor of HER1/EGFR-mediated signaling. This trial of patients with metastatic...
6.
Massard C, Voigt J, Laplanche A, Culine S, Lortholary A, Bugat R, et al.
Br J Cancer
. 2007 Sep;
97(7):857-61.
PMID: 17876336
Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study...
7.
Delord J, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, et al.
Br J Cancer
. 2007 Jul;
97(3):297-301.
PMID: 17637682
This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur-uracil (UFT) with leucovorin (LV) combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line...
8.
Le Cesne A, Landi B, Bonvalot S, Monges G, Ray-Coquard I, Duffaud F, et al.
Ann Pathol
. 2006 Nov;
26(3):231-4.
PMID: 17127860
No abstract available.
9.
Delord J, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, et al.
Ann Oncol
. 2005 Oct;
16(12):1889-97.
PMID: 16219625
Although first-line chemotherapy induces complete clinical remission in many cases of epithelial ovarian cancer, relapse usually occurs 18-28 months from diagnosis owing to micrometastases. The present study aimed to evaluate...
10.
Delord J, Pierga J, Dieras V, Bertheault-Cvitkovic F, Turpin F, Lokiec F, et al.
Br J Cancer
. 2005 Mar;
92(5):820-6.
PMID: 15756252
Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment. The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to...